Platelet glycoprotein Ibα polymorphisms and function evaluated by the platelet function analyzer PFA-100 in patients with lupus anticoagulant: the association with thromboembolic disease

Jilma-Stohlawetz, Petra; Jilma, Bernd; Mannhalter, Christine; Bencur, Peter; Pabinger, Ingrid; Vormittag, Rainer; Dunkler, Daniela; Panzer, Simon
October 2007
Annals of Hematology;Oct2007, Vol. 86 Issue 10, p719
Academic Journal
Lupus anticoagulants (LA) are a surrogate marker for the risk of thromboembolic disease (TE). However, not all individuals with LA acquire TE, and it is desirable to distinguish those at risk for TE from those without. Platelets polymorphisms may contribute to the risk of TE, mainly those of glycoprotein (GP)Ibα: these are the variable number of tandem repeats (VNTR) and a dimorphism in the Kozak region, which affect platelet plug formation in healthy individuals under high shear stress rates. We determined polymorphisms within the GPIbα in individuals with persistent LA and a history of TE (LA/TE+) and in those without TE (LA/TE-). Further, we measured platelet function, as estimated by the collagen-epinephrine closure time (CEPI-CT) of the platelet function analyzer PFA-100 and compared all data with healthy controls. There was no difference of the VNTR alleles compared to healthy controls. The (−5)C allele of the Kozak dimorphism was significantly more frequent in LA patients compared to controls ( p = 0.04), as a result of its increased frequency in LA/TE+ (vs controls p = 0.04), but there was no difference between LA/TE+ and LA/TE−. The increased frequency of the (−5)C allele resulted in an overrepresentation of (−5)TC genotype in the LA/TE+ group ( p = 0.02) but not in a subgroup of 18 patients with arterial disease. The CEPI-CT of the PFA-100 was shorter in LA/TE+ than in LA/TE− ( p = 0.044), but this difference did not persist after exclusion of patients with low platelet counts or low ristocetin cofactor activity. Unlike in healthy individuals, the CEPI-CT was not related to any Kozak dimorphism, neither in LA/TE−, nor in LA/TE+. Thus, the Kozak dimorphism may just contribute to stronger factors disposing individuals with LA towards TE without any discernible effect on their in vitro platelet function estimated by the PFA-100.


Related Articles

  • Balancing the Expression and Production of a Heterodimeric Protein: Recombinant Agkisacutacin as a Novel Antithrombotic Drug Candidate. Guo, Yugang; Ma, Jiajia; Sun, Jie; Tian, Zhigang; Xiao, Weihua; Wu, Jing; Chen, Wei; Shao, Changsheng; Zhao, Lei; Jia, Hao; Li, Rui; Zhong, Yongjun; Fang, Fang; Wang, Dong; Qian, Fang; Dai, Xiangrong; Zhang, Guohui; Xiaoyi Li, Benjamin // Scientific Reports;7/10/2015, p11730 

    Agkisacucetin extracted from the venom of Agkistrodon acutus has been demonstrated to be a promising antithrombotic drug candidate in clinical studies due to its function as a novel platelet membrane glycoprotein (GP) Ib inhibitor. Agkisacucetin is a heterodimeric protein composed of α- and...

  • Abatacept: A Viewpoint by Paul Emery. Emery, Paul // BioDrugs;2006, Vol. 20 Issue 1, p62 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention1. Curran, Monique P.; Keating, Gillian M. // BioDrugs;2006, Vol. 20 Issue 1, p63 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • The Relevance of Platelet Glycoprotein GP IIb/IIIa Polymorphism to Anti-platelets Response in Acute Coronary Syndrome. Naye, Omnia; Sobhy, Mohamed; Baraka, Azza; El Samak, Mohamed; Kader, Sherine Abdel // Annual International Conference on Advances in Biotechnology (Bi;2013, p54 

    The era of pharmacogenomics is intervening in cardiovascular therapeutic armamentarium. In this respect, the potential implication of P1A gene variants of GPIIIa subunit of platelet membrane GP IIb/IIIa as a genetic risk factor provocateur and/or as a therapeutic outcome modulator to...

  • Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab. Stiegler, H.; Fischer, Y.; Steiner, S.; Strauer, B. E.; Reinauer, H. // Annals of Hematology;Mar2000, Vol. 79 Issue 3, p161 

    The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of...

  • Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro). Sharma, Sanjiv; Bhambi, Brijesh; Nyitray, William; Sharma, Geetanjali; Shambaugh, Shawn; Antonescu, Adrian; Shukla, Pankaj; Denny, Eileen // Journal of Cardiovascular Pharmacology & Therapeutics;Jan2002, Vol. 7 Issue 1, p21 

    A case of a 65-year-old woman presenting with delayed profound thrombocytopenia 7 days after the use of abciximab (ReoPro) in the setting of percutaneous coronary intervention is described. The patient had normal platelet counts for the first 24 hours after the use of abciximab (ReoPro). She...

  • Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Pierangeli, S. S.; Erkan, D. // Lupus;Apr2010, Vol. 19 Issue 4, p475 

    Persistently positive antiphospholipid antibodies in association with thromboses and/or pregnancy morbidity is the hallmark of the antiphospholipid syndrome. The management of antiphospholipid antibody-positive patients has been focused on utilizing anti-thrombotic medications such as heparin or...

  • Survival Benefit With Concomitant Oral Platelet Therapy After Coronary Angiography and Before Ad Hoc Percutaneous Coronary Intervention. Patel, Rajan A. G.; White, Christopher J. // Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p978 

    The authors reflect on the medical research conducted by Gumina and colleagues in the U.S. They note that the group performed an interesting retrospective assessment of the value of an intravenous platelet glycoprotein (GP) IIb/IIIa receptor blocker in addition to dual oral antiplatelet therapy...

  • Impact of Thrombophilic Genetic Factors on Pulmonary Embolism: Early Onset and Recurrent Incidences. Ivanov, Petar; Komsa-Penkova, Regina; Kovacheva, Katia; Ivanov, Yavor; Stoyanova, Angelina; Ivanov, Ivan; Pavlov, Plamen; Glogovska, Pavlina; Nojarov, Venzislav // Lung;Jan/Feb2008, Vol. 186 Issue 1, p27 

    The importance of genetic thrombophilic factors in the development of venous thromboembolism has been increasingly recognized. Factor V Leiden (FVL), prothrombin gene mutation G20210A (FII G20210), genetic variant C677T of the methylentetrahydrofolate reductase (MTHFR), as well as the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics